RT Journal Article
A1 Lam, Delphine
A1 Fardeau, Christine
A1 Koné-Paut, Isabelle
A1 Marie, Isabelle
A1 Mouriaux, Frederic
A1 Despert, Veronique
A1 Weber, Michel
A1 Couret, Chloe
A1 Lehoang, Phuc
A1 Quartier, Pierre
A1 Bodaghi, Bahram
T1 Evolution of intraocular inflammation after the end of the ADJUVITE study
JF Investigative Ophthalmology & Visual Science
JO Invest. Ophthalmol. Vis. Sci.
YR 2019
VO 60
IS 9
SP 3520
OP 3520
SN 1552-5783
AB    To evaluate the efficacy of adalimumab on uveitis and its tolerance, after the end of the ADJUVITE study.    Retrospective, descriptive study of patients who were enrolled in the ADJUVITE study at Pitié-Salpêtrière, Necker, Kremlin Bicetre , Rennes and Nantes hospitals and evaluation of intraocular inflammation by laser flare meter and Standardization of Uveitis Nomenclature criteria.    Twenty-six patients were included. Median age was 4.0 +/- 3.2 years. Mean follow-up time was 56.3 months (median 58.0 +/- 17.3; range 10-82). At the end of ADJUVITE study, mean visual acuity was 0.16 logMAR. At the last follow-up visit, mean visual acuity was 0.17 logMAR. Mean laser flare meter value was 46.8 photons/ms at the end of ADJUVITE study and 32.6 photons/ms at last follow-up visit. Twenty-three patients on adalimumab had good uveitis control.    Adalimumab was well tolerated and efficient in maintaining good uveitis control in Juvenile Idiopathic Arthritis- associated uveitis, when conventional immunosuppressors were not sufficient. Most of the children were dependent on adalimumab. Further investigations are needed to determine the rhythm of tapering and duration of therapy in these children.  This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019. 
RD 3/5/2021